Lumateperone
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The FDA has approved lumateperone tosylate (Caplyta™, Intra-Cellular Therapies) for treatment of schizophrenia in adults.
Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone… Abstract Background Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of…
Abstract Background Oxidative stress, coupled with dysregulation of inflammation, NMDAR and dopamine, is involved in…
Abstract Background The aim of this study was to investigate the efficacy and safety of blonanserin treatment after switching…
Abstract Background A six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted…